Dissolution of Ionizable Drugs in Buffered and Unbuffered Solutions
Overview
Authors
Affiliations
The dissolution kinetics of ionizable drugs (weak acids or bases) are analyzed with a mathematical model derived from the theory of mass transfer with chemical reaction. The model assumes that the overall process is diffusion limited, that all the reactions are reversible and instantaneous, and that dissolution and reaction are limited to the stagnant fluid film adjacent to the solid phase. Dissolution into buffered and unbuffered aqueous solutions are considered separately, with convenient analytical solutions obtained in both cases. In addition, equations for the time to partial and complete dissolution are derived. The dissolution rate is shown to be dependent on the pKa and intrinsic solubility and the medium properties, i.e., pH, buffer capacity, and mass transfer coefficient. Equations of a form analogous to the nonionized case are derived to account explicitly for all these factors, with dissolution rates expressed in terms of the product of a driving force (concentration difference) and resistance (inverse of mass transfer coefficient). The solutions are in an accessible analytical form to calculate the surface pH and subsequently the surface concentrations driving the drug dissolution. Numerical examples to illustrate dissolution into unbuffered and buffered media are presented and the results are shown to be in accord with experimental data taken from the literature.
Arav Y Pharmaceutics. 2024; 16(8).
PMID: 39204323 PMC: 11359797. DOI: 10.3390/pharmaceutics16080978.
Solubility vs Dissolution in Physiological Bicarbonate Buffer.
Claussen F, Al-Gousous J, Salehi N, Garcia M, Amidon G, Langguth P Pharm Res. 2024; 41(5):937-945.
PMID: 38698196 PMC: 11116206. DOI: 10.1007/s11095-024-03702-5.
Kowthavarapu V, Charbe N, Gupta C, Iakovleva T, Stillhart C, Parrott N AAPS J. 2024; 26(3):44.
PMID: 38575716 DOI: 10.1208/s12248-024-00912-y.
Lost in modelling and simulation?.
Sugano K ADMET DMPK. 2022; 9(2):75-109.
PMID: 35299768 PMC: 8920108. DOI: 10.5599/admet.923.
Chirumamilla S, Banala V, Jamei M, Turner D Pharmaceutics. 2021; 13(8).
PMID: 34452130 PMC: 8398830. DOI: 10.3390/pharmaceutics13081169.